Memo Advances Kidney Transplant Infection Drug Despite Phase II Miss

Memo advances kidney transplant infection drug despite Phase II miss

Memo Therapeutics will discuss the Phase III trial design for potravitug in kidney transplant infection with regulators by the end of 2025.The post Memo advances kidney transplant infection drug despite Phase II miss appeared first on Clinical Trials Arena.

Memo Therapeutics says there’s still a path forward for kidney transplant drug that failed Phase 2 trial

Memo Therapeutics said Friday it is planning to advance its monoclonal antibody for kidney transplant patients with a viral infection into Phase 3 even though the drug didn’t pass a mid-stage test. The candidate, known ...